News
In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations ...
Healthcare professionals must stop supplying the affected batch, quarantine stock, and return it to suppliers.
Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian ...
The VISTA trial is evaluating and comparing 2 dose levels of laru-zova to an untreated control group for the treatment of ...
Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...
Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...
EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in ...
Beacon Therapeutics has exercised its option agreement to license Abeona Therapeutics’ patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases ...
Dry eye is top of mind for optometrists year-round, but Prevent Blindness has declared July as Dry Eye Month in hopes to raise awareness among the public and the eye care industry. To support this, ...
Researchers at Yale School of Medicine have identified in a new study a novel, noninvasive method for diagnosing bacterial corneal ulcers, a serious ophthalmologic condition that can lead to vision ...
Key Takeaways RGN-259, a thymosin beta-4–based eye drop, failed to meet the primary endpoint in a European phase 3 trial for neurotrophic keratitis. The trial's unexpected outcome was attributed to a ...
ModMed conducted a new survey on 2000 US patients on their comfort with artificial intelligence (AI) use in medical practices. Survey results showed that patients still feel uneasy about AI use in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results